Bavarian Nordic

Biotechnology company, Bavarian Nordic, has revealed positive data from the extension study of its Phase II study investigating its universal respiratory syncytial virus (RSV) vaccine, MVA-BN RSV, in older adults. Read more


Johnson & Johnson has accelerated its Phase 1, first-in-human clinical trial of a preventive Ebola vaccine, with Chief Scientific Officer Paul Stoffels stating "every day counts". Read more


This immunotherapy is designed to induce a robust immune response against Brachyury, a tumour-associated antigen which is overexpressed in every major solid tumour setting Read more